^
    over1year
    RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: a phase I trial. (PubMed, EClinicalMedicine)
    CT017 CAR T cells were engineered to co-express CAR-GPC3 and runt-related transcription factor 3 (RUNX3), which triggers CD8 T-cell infiltration into the cancer microenvironment...These results need to be confirmed in a robust clinical trial. This study was funded by CARsgen Therapeutics Co., Ltd.
    P1 data • Journal • CAR T-Cell Therapy • Metastases
    |
    CD8 (cluster of differentiation 8) • GPC3 (Glypican 3) • TCF3 (Transcription Factor 3) • RUNX3 (RUNX Family Transcription Factor 3)
    |
    GPC3 expression • GPC3 positive
    |
    CT017 • CT0180